Actively Recruiting
Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer
Led by Henan Cancer Hospital · Updated on 2024-05-09
20
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
Sponsors
H
Henan Cancer Hospital
Lead Sponsor
K
Kingbio Medical (Beijing) Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study plans to enroll 20 patients with recurrent small cell lung cancer. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.
CONDITIONS
Official Title
Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years old at the time of informed consent
- Diagnosed with recurrent small cell lung cancer
- Have had at least one systemic treatment and disease has progressed
- At least one lesion suitable for tumor tissue sampling that has not received radiation or other local therapy
- ECOG Performance Status score between 0 and 2
- Expected survival time of 3 months or more
- Documented disease progression on imaging after previous treatment before tumor sampling
- Signed informed consent form
- Good compliance and willingness to follow study procedures, including visits, treatments, and tests
You will not qualify if you...
- Extremely weak overall condition preventing bronchoscopy examination
- Acute respiratory tract infection with high fever, acute asthma attacks, or ongoing hemoptysis
- History of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases like diabetes, hypertension, pulmonary fibrosis, or acute lung disease
- Active leptomeningeal disease or brain metastases
- Other malignant diseases diagnosed within 5 years before study start (except certain skin cancers and carcinoma in situ)
- History of immunodeficiency, including positive HIV tests
- Untreated active hepatitis B infection
- Any serious or uncontrolled systemic diseases
- Pregnant or breastfeeding women
- Any condition deemed unsuitable for participation by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
Research Team
Q
Qiming Wang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here